Acta Pharmaceutica, Vol. 71 No. 3, 2021.
Original scientific paper
https://doi.org/10.2478/acph-2021-0022
Amygdalin isolated from Amygdalus mongolica protects against hepatic fibrosis in rats
JIA WANG
; Department of Pharmacy, Baotou Medical College, Baotou, Inner Mongolia, China, 014040; Institute of Bioactive Substance and Mongolian Medicine and Chinese Materia Medica, Baotou, Inner Mongolia, China, 014040
HONGBING ZHOU
; Department of Pharmacy, Baotou Medical College, Baotou, Inner Mongolia, China, 014040; Institute of Bioactive Substance and Mongolian Medicine and Chinese Materia Medica, Baotou, Inner Mongolia, China, 014040
TONG WU
; Department of Pharmacy, Baotou Medical College, Baotou, Inner Mongolia, China, 014040; The Third Staff Hospital of Baogang Group, Baotou, Inner Mongolia, China, 014010
PEISAI WU
; Department of Pharmacy, Baotou Medical College, Baotou, Inner Mongolia, China, 014040; Hunan University of Medicine, Huaihua, Hunan, China, 418000
QUANLI LIU
; Institute of Bioactive Substance and Mongolian Medicine and Chinese Materia Medica, Baotou, Inner Mongolia, China, 014040
SONGLI SHI
; Department of Pharmacy, Baotou Medical College, Baotou, Inner Mongolia, China, 014040
Abstract
The aim of this research was to investigate the effect of amygdalin on hepatic fibrosis in rats. Amygdalin was purified and identified from the seeds of Amygdalus mongolica. Sprague Dawley rats in the control and model groups were administered water. Sprague Dawley rats were divided into the low-, middle-, and high-dose amygdalin groups that received 20, 40, and 80 mg kg–1 amygdalin, respectively. whereas the silymarin group was treated with 50 mg kg–1 silymarin. The control and model groups were administered water. Liver tissue analysis revealed significantly lower activities of ALT, AST, ALP, SOD, and MDA in the drug-treated groups compared to the model group. Serum analysis revealed significantly lower HYC and C-IV in the middle-dose amygdalin-treated group compared to the model group. The histopathological changes were less severe in the drug-treated groups as observed by the formation of pseudolobuli and decreased collagen fiber deposition. Hepatic fibrosis-related genes were expressed at significantly lower levels in the amygdalin-treated groups than in the model group. Amygdalin from A. mongolica represents a therapeutic candidate for hepatic fibrosis prevention and treatment.
Keywords
amygdalin; Amygdalus mongolica, hepatic fibrosis, rat model, traditional Chinese medicine
Hrčak ID:
242230
URI
Publication date:
30.9.2021.
Visits: 1.462 *